Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Akamai Technologies, Inc. (AKAM) vs Cardinal Health Inc (CAH) Price & Performance

Akamai Technologies, Inc.Trade
Cardinal Health IncTrade

Price performance (Past 24H)

Key statistics

Akamai Technologies, Inc. vs Cardinal Health Inc — how do they compare? Akamai Technologies, Inc. trades at $122.5 (market cap $16.77B), while Cardinal Health Inc trades at $234.16 (market cap $55.88B). The key difference: Cardinal Health Inc is far larger — about 3.3× Akamai Technologies, Inc.'s market cap, and Cardinal Health Inc pays a 0.86% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.

AKAMCAH
Market Cap
$16.77B$55.88B
Sector
TechnologyHealth
52-Week High
$161.14$240.26
52-Week Low
$71.97$146.04
Enterprise Value
$22.75B$59.91B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Akamai Technologies, Inc.

Akamai Technologies (AKAM) trades at $122.67, up 4.27% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with $4.21B revenue and 57.45% gross margins. Recent analyst upgrades and a $600M cloud contract highlight growth potential in AI and cybersecurity services.

Outlook remains cautiously optimistic with a $150.11 consensus price target offering 22% upside, though margin compression and competitive pressures present risks. Institutional sentiment leans neutral with 49% hold ratings, requiring monitoring of Q3 earnings execution and infrastructure investment returns.

Cardinal Health Inc

Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.

The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Akamai Technologies, Inc.

Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.

Read more on AKAM

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH